| Patient |
T stage |
Gleason score |
PSA at diagnosis (ng/ml) |
PSA at
imaging (ng/ml) |
PSA at last follow-up (ng/ml) |
Time between RT and last follow-up (month) |
| 1 |
cT3a |
3+3 |
38.0 |
0.10 |
0.12 |
92 |
| 2 |
cT3a |
3+3 |
20.0 |
0.35 |
0.30 |
72 |
| 3 |
cT3a |
3+4 |
33.5 |
<0.04 |
0.01 |
85 |
| 4 |
cT2 |
3+3 |
33.7 |
0.09 |
<0.04 |
91 |
| 5 |
cT3a |
5+5 |
4.9 |
0.45 |
0.37 |
99 |
| 6 |
cT3b |
3 +3 |
6.7 |
0.07 |
0.08 |
87 |
| 7 |
cT3b |
4+3 |
7.5 |
0.46 |
0.55 |
87 |
| 8 |
cT2b |
4+4 |
14.0 |
0.08 |
0.03 |
81 |
| 9 |
cT2a |
3+3 |
4.9 |
0.38 |
0.57 |
120 |
| 10 |
cT3a |
3+3 |
13.7 |
0.23 |
1.39 |
108 |
| 11 |
cT3a |
3+4 |
9.3 |
0.23 |
0.26 |
98 |
| 12 |
cT1c |
3+3 |
5.3 |
0.27 |
0.3 |
92 |
| 13 |
cT2a |
3+4 |
13.7 |
0.33 |
0.28 |
91 |
| 14 |
cT3a |
4+3 |
10.4 |
<0.04 |
<0.04 |
92 |
| 15 |
cT3a |
3+3 |
15.2 |
0.05 |
0.08 |
80 |
| 16 |
cT1c |
3+3 |
4.1 |
0.05 |
0.46 |
125 |
| 17 |
cT3a |
4+4 |
8.8 |
0.15 |
0.15 |
76 |
| 18 |
cT2b |
3+4 |
14.9 |
<0.04 |
<0.04 |
74 |
| 19 |
cT1c |
3+3 |
8.0 |
0.18 |
0.25 |
105 |
| 20 |
cT2a |
3+2 |
9.3 |
0.25 |
0.27 |
128 |
|
